E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029883 |
E.1.2 | Term | Obesity |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To examine the long term efficacy of CP 945,598 in prevention of weight regain in obese or overweight subjects over 12 months after previous weight loss (WL)induced by an 8 week low calorie diet (LCD) |
|
E.2.2 | Secondary objectives of the trial |
To determine the effect of CP-945,598 at the end of the 12 month treatment period on: • The proportion of subjects maintaining at least 25%, 50%, 75% or 100% of their initial weight loss achieved during the LCD; • Changes in waist circumference; Changes in triglycerides and HDL; • Changes in Patient Reported Outcome Scales; • Uncontrolled Eating (from the Three Factor Eating Questionnaire R 21); • Power of Food (from the Power of Food Scale, USA or AMOTPIOTFE, exUSA). |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Resting Energy Expenditure Sub-Study to be conducted in some sites in Denmark. This is a sub.study of protocol A5351028 and details are included in protocol amendment #3, dated 28 September 2007.
The purpose of the this study it to assess the effect of CP-945,598 10 mg and 20 mg QD (as compared to placebo) after a 3 month treatment period, on resting energy-expenditure (REE), substracte utilisation and body composition in obese subjects, or overweight subjects with co-morbid conditions.
Primary objective: To examine the effect of CP-945,598 on resting metabolic rate (RMR) in obese or overweight subjects after a 3 month treatment period.
Secondary objectives: To evaluate the effect of CP-945,598 on REE and substrate utilisation after a standardized meal. To evaluate the effect of CP-945,598 on body composition. To evalute the effect of CP-945,598 on appetite in response to a standardized meal. |
|
E.3 | Principal inclusion criteria |
1. Male and/or female subjects between 18 and 70 years of age, inclusive. 2. For women of childbearing potential, a negative serum pregnancy test will be required prior to study inclusion. Female subjects must be surgically sterile or postmenopausal or must agree to use effective contraception during the study. Note: Oral contraceptive use is permitted if used for at least 3 months before starting study medication. Note: The definition of effective contraception will be based on the judgment of theInvestigator or a designated associate. 3-Body Mass Index (BMI) ≥30 kg/m2, for subjects without co-morbidities or BMI ≥27 kg/m2 for subjects with co-morbidities [treated or untreated hypertension and/or treated or untreated dyslipidemia]: • Treated or untreated hypertension is defined as: a. Blood pressure ≥140/90 mmHg and/or; b. On anti-hypertensive medication. AND/OR • Treated or untreated dyslipidemia is defined as: c. LDL mg/dL not at goal according to local guidelines, and/or; d. HDL <40 mg/dL, and/or; e. Triglycerides ≥150 mg/dL, and/or; f. On any anti-dyslipidemic medication. Note: Treated subjects for hypertension and/or dyslipidemia should have been on stable therapy for at least 2 months prior to screening. 4. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial. 5. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.
|
|
E.4 | Principal exclusion criteria |
1.Women who are pregnant or lactating, or who are planning to become pregnant; 2.Subjects with clinically significant abnormalities identified during the screening process. Specific exclusions include but are not limited to the following: a.Subjects with systolic BP ≥ 160 and/or diastolic BP ≥ 100 mmHg or requiring new pharmacologic treatment or change in current treatment according to local guidelines; b.Subjects with clinically significant cardiovascular disease, defines as unstable coronary heart disease (CHD), cerebrovascular disease (CVD) or peripheral vascular disease (PVD) and/or an event/intervention during the past 6 months Note: Clinically stable subjects with a history of CHD, CVD or PVD, provided that the level of exercise proposed in the trial is deemed safe and appropriate for the subject may be included. c.Subjects with dyslipidemia requiring new pharmacological treatment or a change in current treatment according to local guidelines; d.Subjects with diabetes or fasting blood glucose concentration of ≥126mg/dL. e.Subjects with renal disease including: •Any history of nephrotic syndrome •Chronic renal failure and/or serum creatinine >1.5 times the upper limit of normal f.Subjects with abnormal screening TSH values. Mildly abnormal TSH may be allowed; g.Subjects with significant hepatobiliary disease including: •History of hepatitis B or C infection and/or, •Aspartate aminotransferase or alanine aminotransferase ≥2 times the ULN. h.History of HIV infection or use of antiretroviral agents; i.Subjects with any prior history of malignancy except for: 1.Basal cell carcinoma of the skin curatively treated, 2.Other malignancies (regardless of site) that have been cancer-free for greater than 5 years prior to screening. j.Subjects with gastrointestinal disease, surgery limiting drug absorption or previous history of surgical procedure for weight loss; k.Clinically significant laboratory tests outside the pre-specified exclusionary limits; l.Subjects with a history of CNS disorder including: •A mood disturbance that meets the criteria for a Major Depressive Disorder within the last 2 years. •Use of antidepressants that are known to increase weight; Note: Subjects on a maintenance dose of a permitted antidepressant for a major depressive disorder, stable and in remission for at least 3 months prior to screening, and who plan to continue this treatment during the entire trial may be included. •PHQ score of ≥10 and/or a positive score to PHQ item 9 addressing suicidal ideas Note: It may be possible to include some subjects with a total PHQ score between 10-14, but who do not score positively on item 9 addressing suicidal ideas. However, these subjects will require further assessment to rule out a Major Depressive Disorder and other risk factors outlined in exclusion criterion L above prior to inclusion. •Any response to the C-SSRS interviews that indicates potential suicidality; •Subjects with severe psychiatric disorders such as psychotic conditions or on antipsychotic pharmacotherapy; •Subjects with seizure disorders who: 1.Are not controlled by current antiepileptic treatment, and/or 2.Are taking antiepileptic drugs (AEDs) That are known to affect weight positively or negatively unless these medications have been taken at a stable dose for at least 6 months and the subject’s weight has been stable over the same time period and/or That may increase the risk of a drug-drug interaction. •Subjects with neurological disorders that are acute, chronic relapsing, progressive or have an unpredictable course. 3.Subjects who smoke marijuana (by history). 4.Subjects who frequently change smoking habits or have stopped smoking within 6 months prior to screening. 5.Subjects with known history of alcoholism or drug abuse or dependence within 1 year prior to screening. 6.Subjects with a history of anorexia, bulimia nervosa or binge eating disorder 7.Use of prescription drugs or over the counter agents/supplements known to alter body weight or appetite within 3 months prior to screening. 8.Systemic therapy with strong CYP3A inhibitors or regular consumption of grapefruit/grapefruit juice (mild to moderate CYP3A inhibitors). 9.Systemic therapy with clinically significant CYP3A inducers 10.Treatment with an investigational drug during the 30 days prior to screening. 11.Participation in any formal weight loss program within the 3 months prior to screening. 12.Fluctuation in body weight >5% within 3 months prior to screening. 13.Subjects with any other medical condition or laboratory abnormality prior to randomization, which in the opinion of the investigator or sponsor could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study. 14.Subject intends to donate blood or blood products during the period of the study or within one month of the study’s completion.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Percent weight regained during the 12 month treatment period after a prior weight loss on the low calorie diet (8 weeks). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 0 |